Likewise, no increase of pancreatitis or pancreatic carcinoma was detected in recent large-scale, placebo-controlled, double-blind trials of DPP-4 inhibitors, including SAVOR-TIMI 53 and EXAMINE. The gene discussed is DPP4; the disease is exocrine pancreatic carcinoma.